Transgenomic, Inc., a biotechnology company, engages in advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies, and clinical and research services primarily in the United States. The company provides genetic analytical laboratory services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. It employs various genomic testing service technologies, including ICE COLD-PCR, a proprietary platform technology that enables detection of multiple known and unknown mutations from virtually any sample type, including tissue biopsies, blood, urine, saliva, cell-free DNA, and circulating tumor cells. The company was founded in 1997 and is headquartered in Omaha, Nebraska.
